Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Apr 2, 2002; 99(7): 4227–4232.
Published online Mar 26, 2002. doi:  10.1073/pnas.032068299
PMCID: PMC123630

Paranodal junction formation and spermatogenesis require sulfoglycolipids


Mammalian sulfoglycolipids comprise two major members, sulfatide (HSO3-3-galactosylceramide) and seminolipid (HSO3-3-monogalactosylalkylacylglycerol). Sulfatide is a major lipid component of the myelin sheath and serves as the epitope for the well known oligodendrocyte-marker antibody O4. Seminolipid is synthesized in spermatocytes and maintained in the subsequent germ cell stages. Both sulfoglycolipids can be synthesized in vitro by using the isolated cerebroside sulfotransferase. To investigate the physiological role of sulfoglycolipids and to determine whether sulfatide and seminolipid are biosynthesized in vivo by a single sulfotransferase, Cst-null mice were generated by gene targeting. Cst−/− mice lacked sulfatide in brain and seminolipid in testis, proving that a single gene copy is responsible for their biosynthesis. Cst−/− mice were born healthy, but began to display hindlimb weakness by 6 weeks of age and subsequently showed a pronounced tremor and progressive ataxia. Although compact myelin was preserved, Cst−/− mice displayed abnormalities in paranodal junctions. On the other hand, Cst−/− males were sterile because of a block in spermatogenesis before the first meiotic division, whereas females were able to breed. These data show a critical role for sulfoglycolipids in myelin function and spermatogenesis.

A considerable body of data has accumulated to date on the biological importance of sulfated glycoconjugates (16). Two major sulfated glycolipids exist in the mammal: the sulfatide HSO3-3-galactosylceramide (GalCer), which is a sphingolipid, and the seminolipid HSO3-3-monogalactosylalkylacylglycerol (GalEAG), which is a glycerolipid (7, 8). Sulfatide is a major lipid component of the myelin sheath and is synthesized in the oligodendrocytes in the central nervous system, as well as Schwann cells in the peripheral nervous system. Sulfatide serves as one of the epitopes for the well known oligodendrocyte-marker antibody O4 (9). Seminolipid is synthesized in spermatocytes and maintained in the subsequent germ cell stages (7, 8). The fact that the distribution of sulfoglycolipids is tissue-specific suggests that their biological roles are at the sites where they are expressed (7, 8). Despite the volume of findings as the result of in vitro experiments with exogenous sulfoglycolipids (7), definitive evidence relating to their physiological functions has not yet appeared.

The sulfate group of the sulfoglycolipids is transferred from 3′-phosphoadenosine 5′-phosphosulfate by means of catalysis by a glycolipid-specific sulfotransferase, GalCer sulfotransferase [cerebroside sulfotransferase (CST); EC], which is located in the Golgi membranes (7). CST has been purified to apparent homogeneity from human renal cancer cells (10), and its cDNA has been cloned (11). The mouse and human CST genes have also been cloned (12, 13). The purified CST was found to catalyze the synthesis of seminolipid and sulfatide in vitro (10). A Northern blot analysis of mouse tissues revealed that CST mRNA is expressed in brain, testis, kidney, stomach, small intestine, liver, and lung (12), all of which are tissues where sulfoglycolipids are expressed (7). No reports have been published on the existence of isozymes of CST. These observations suggest that the CST is completely responsible for the biosynthesis of both sulfoglycolipids in vivo.

Insight into the physiological function of sulfoglycolipids was provided by gene-targeted disruption of ceramide galactosyltransferase (CGT) (14, 15). This single enzyme, CGT, is responsible for the biosynthesis of GalCer and GalEAG, which are the precursors of sulfatide and seminolipid, respectively (1416). CGT-knockout mice are completely devoid of GalCer and sulfatide in the brain (14, 15) and of GalEAG and seminolipid in the testis (16). CGT-deficient mice manifest neurological disorders caused by myelin dysfunction (14, 15) and the complete inhibition of spermatogenesis at the late-pachytene spermatocyte stage (16). These results provide strong support for the view that the intermediate products, GalCer and GalEAG, and/or the end products, sulfatide and seminolipid, are indispensable for myelin function and spermatogenesis. However, the creation of sulfotransferase-deficient mice would be highly desirable to understand completely the functions of the precursor galactolipids and their sulfated products (1416).

To address this problem and to determine whether a single enzyme is responsible for the biosynthesis of both sulfatide and seminolipid in vivo, CST-deficient mice were created by means of gene targeting. CST-knockout mice demonstrated the essentiality of sulfoglycolipids in at least two physiological processes.

Materials and Methods

Gene Targeting.

Overlapping λ clones encompassing Cst were isolated from a mouse 129SvJ genomic library and sequenced (12). A targeting vector was constructed by inserting a 1.6-kb pgk-neo cassette between two homologous flanking fragments of 7.7 kb (XbaI–SacI) and 1.1 kb (SacI-SpeI), flanked with a phsv-tk gene. A linearized vector (30 μg) was transfected into E14.1 embryonic stem cell line. Clones were selected with G418 and ganciclovir. An analysis of selected clones by Southern blot with 5′ and 3′ probes (Fig. (Fig.1)1) revealed that 10% (12 of 121) of the embryonic stem clones had undergone correct homologous recombination. Targeted cell clones were then injected into C57BL/6 blastocysts. Germ-line transmission of the mutant allele was achieved from male chimeras derived from embryonic stem clone cst no. 98 and cst no. 112.

Figure 1
Targeted disruption of the Cst locus and the establishment of a mutant mouse strain. (A) The Cst gene (wild allele; Top), the targeting vector (Middle), and the disrupted Cst locus (mutated allele; Bottom). Boxes represent exons. Black boxes indicate ...

Animals and Tissue Processing for Light and Electron Microscopy Studies.

For morphological investigations of the nervous system, Cst−/− mice and their littermate controls, ranging from 13 to 36 weeks in age, were anesthetized with ether and perfused with 4% paraformaldehyde alone or a solution containing 4% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M sodium phosphate buffer (pH 7.4). They were immersed in the same fixative for several days. The brain, optic nerve, and spinal cord were then removed. Tissues were processed for paraffin and plastic embedding, sectioned, and examined by light microscopy as described (17). The paraffin sections were stained with solochrome and eosin, Luxol fast blue/periodic acid Schiff, and Bielschowsky stains. Plastic-embedded tissues were sectioned 1 μm thick and stained with toluidine blue. Selected areas of the plastic-embedded cerebellar tissues were thin-sectioned, double-stained with uranyl acetate and lead citrate, and examined by electron microscopy.

Testes were dissected, fixed in Bouin's solution, and embedded in paraffin. Sections (7 μm) were prepared and stained with hematoxylin/periodic acid Schiff reagent. In situ labeling of apoptotic cells was performed on tissue sections prepared in the same manner with an in situ Apoptosis Detection kit (Takara Shuzo, Kyoto), according to the manufacturer's protocol.

Electrophysiological Analysis.

Peripheral and central nerve conduction velocity was measured in a total of 24 mice (5 Cst−/− and 19 wild-type). Each animal was initially sedated with halothane, and then anesthetized with Nembutal (0.06–0.1 mg/kg, i.p.). The sciatic nerve was exposed and single stimulating pulses (0.1-ms duration, 0.1–1 mA, at 1/s) were applied to the proximal and distal portions of the sciatic nerve, while compound electromyographic activity of the triceps surae muscle was recorded by using bipolar electrodes placed on the muscle. The latency of the direct response (i.e., M wave) was recorded. Maximal motor nerve conduction velocity was measured by dividing the latency difference recorded at the two sites by the distance between the two points. For several mice, conduction velocity was examined bilaterally. Central nerve conduction velocity was estimated in two Cst−/− and two wild-type mice by recording pyramidal tract volleys of the dorsal column at C1 from the spinal cord surface in response to stimulation of the sensorimotor cortex by using bipolar electrodes, which were positioned on the pial surface. Single stimulating pulses (0.1-ms duration, 1–5 mA) were applied at 10 Hz. The direct (not synaptic) response was confirmed as fixed latency during high-frequency stimulation. Because no sensory fibers project directly to the sensorimotor cortex, a direct response must be the result of pyramidal tract activation. Only the latency of the direct response was measured and compared between the two groups. That response is a reflection of fastest pyramidal tract fibers. All experiments were performed in strict compliance with the Guide for the Care and Use of Laboratory Animals (18). Specific protocols were approved by the Animal Care and Use Committee of Hokkaido University School of Medicine (protocol no. 11090).

Lipid Extraction and Separation of Acidic Glycolipids.

Total lipid was extracted from brain and testis with chloroform/methanol/water (30:60:8 by volume) followed by chloroform/methanol (2:1 by volume). The extracts were combined and applied to a DEAE-Sephadex A-25 (Amersham Pharmacia) column. After washing with chloroform/methanol/water (30:60:8 by volume) and methanol, acidic glycolipids were eluted with 200 mM ammonium acetate in methanol and desalted with a SepPak C18 cartridge (Waters).

Northern Blot Analysis.

Total brain RNA (20 μg) was denatured in 50% (vol/vol) formamide, 6% (vol/vol) formaldehyde, 20 mM Mops (pH 7.0) at 65°C, electrophoresed in 1% agarose gel containing 6% formaldehyde, transferred to a nylon membrane (Roche Diagnostics), and hybridized with a digoxigenin-labeled (−) strand RNA probe as described (12). To generate RNA probes, cDNA fragments of Cgt (accession no. L21698), Mag (M31811), Mbp (M15060), and Plp (M15442) were obtained by reverse transcription (RT)–PCR and subcloned into pGEM-T vector (Promega).

RT-PCR Analysis.

Total testicular RNA (2 μg) was reverse-transcribed with an oligo(dT) primer. The resulting cDNA was amplified by PCR by using the following primer sets: Hlf3 (accession no. X72805), 5′-TCTTGACCATGTCGGAAACG-3′ and 5′-CTTTGGCGGGGCTTTTACGT-3′; Sprm-1 (L23864), 5′-CTATGTTTGGGAAGGTTCTC-3′ and 5′-CCTCACTAAGTCAGAGAACT-3′; Ccna1 (X84311), 5′-GCTGTGGCTTACTAGGCAAT-3′ and 5′-GCTGCTTCCTCATGTAGTGA-3′; Cdc25c (U15562), 5′-GTTAACTGGCAAGGATTTTC-3′ and 5′-GAATTCACAGAGGAACACAA-3′; Prm1 (K02926), 5′-TCACAGGTTGGCTGGCTCGA-3′ and 5′-ATTGGCAGGTGGCATTGTTC-3′; βactin (X03672), 5′-TTACCAACTGGGACGACATG-3′ and 5′-AGGAGCCAGAGCAGTAATCT-3′.

Results and Discussion

A targeted disruption of Cst was generated through homologous recombination in embryonic stem cells. The targeting construct was designed to replace the exon portions which encode for the transmembrane domain and the 5′-3′-phosphoadenosine 5′-phosphosulfate-binding motif (19) with a neomycin-resistance cassette (Fig. (Fig.11A). Genotypes of pups from intercrosses between heterozygous mice were determined by Southern blotting (Fig. (Fig.11B). Cst−/− mice were born with approximately the expected Mendelian inheritance, indicating that CST is not critical for embryonic development. Northern blot analysis of brain RNA (Fig. (Fig.22C) and RT-PCR analysis of testicular RNA (Fig. (Fig.33E) showed that expression of full-length Cst mRNA was abolished in homozygous mice. Moreover, CST activity levels in brain and testis were correlated with its gene dosage (Fig. (Fig.11C), indicating that no other isozyme is expressed in these tissues.

Figure 2
Neurological abnormalities in Cst−/− mice. (A) Postural abnormality of Cst−/− mice. The mutant mice dragged their hindlimbs during walking and their posture was flat because of the hindlimb weakness. Knockout mice were ...
Figure 3
Spermatogenesis abnormalities in Cst−/− mice. (A) Male genital organs from 8-week-old wild-type (+/+) and homozygous mutant (−/−) littermates. (B) Glycolipid analysis of testes from 8-week-old ...

Cst−/− mice were born healthy, but began to display hindlimb weakness by 6 weeks of age (Fig. (Fig.22A). These mutant mice subsequently showed a pronounced tremor and progressive ataxia. Involuntary movement also appeared in some Cst−/− mice. The Cst-null mice, however, are able to survive to more than 1 year of age. The phenotype of the CST-deficient mice was milder than that of CGT-deficient mice in terms of the age of onset, life span, and the severity of symptoms (14, 15). Cst−/− mice showed a complete loss of sulfatide in brain (Fig. (Fig.22B), proving that only one Cst gene is responsible for the biosynthesis of sulfatide in the myelin sheath. No changes in other glycolipid composition, including GalCer (Fig. (Fig.22B), were detected, suggesting that loss of sulfatide is the primary cause of the neurological disorder. No differences in the level of cholesterol sulfate (data not shown) were detected, indicating that other sulfotransferase(s) are responsible for its biosynthesis. Although the expression of Cst gene was completely eliminated in the homozygous mutant mouse, no changes in mRNA expression levels of myelin-specific proteins CGT, myelin-associated glycoprotein, myelin basic protein, and proteolipid protein were observed (Fig. (Fig.22C), suggesting that Cst−/− oligodendrocytes undergo the normal differentiation process.

Histological analysis revealed that axons were well myelinated in Cst−/− mice, but myelin vacuolation was observed in the cerebellar white matter, diencephalon, brainstem, and the spinal anterior column as noted in CGT-deficient mice (14), although in a lesser degree (Fig. (Fig.2D2D Left). In addition, focal axonal swelling (axonal spheroid formation) was conspicuous in the cerebellar white matter and in the granular layers (Fig. (Fig.2D2D Right), suggesting secondary neuronal degeneration caused by abnormalities in myelination (20). Electron microscopic analysis of myelinated nerve fibers revealed disorganized termination of the lateral loops at the node of Ranvier, similar to that reported in Cgt−/− mice (21) (Fig. (Fig.22E). Detailed analysis of the fine structure at the axoglial junction is not yet complete. Sulfatide may play a role in nodal formation by mediating axoglial interactions as an adhesion molecule for cell–cell interactions as reported (7). Despite the significant symptoms and morphological abnormalities observed here, maximal nerve conduction velocity of the sciatic motor nerve and the pyramidal tract fibers remained normal until 18 weeks (Fig. (Fig.22F). The reason for this discrepancy remains to be investigated.

Cst−/− males were infertile, whereas females were able to breed. The average testis weight of the Cst−/− mice (28.2 ± 6.8 mg; n = 8) was approximately 35% of that of wild-type littermates (90.2 ± 12.3 mg; n = 8) at 12 weeks of age (Fig. (Fig.33A). No sperm was observed in the epididymis of Cst−/− males, in contrast to wild-type or heterozygous mice (data not shown). Normal size of the seminal vesicles of CST-knockout mice indicates unaltered Leydig-cell function in the knockout mice (Fig. (Fig.33A). The Cst-null mice lacked seminolipid in the testis (Fig. (Fig.33B), proving that the Cst gene is also responsible for the biosynthesis of seminolipid in vivo. In contrast to the brain, the precursor GalEAG markedly accumulated in Cst−/− testis (Fig. (Fig.33B). Because seminolipid accounts for much more than GalEAG in normal adult testis (16), the blockage of the biosynthetic pathway presumably leads to an accumulation of the precursor. In addition, some change was observed in long-chain glycolipids in the Cst−/− testis (Fig. (Fig.33B), which may reflect the difference in the population of resident germ cells.

Histologically, haploid cells and secondary spermatocytes were absent from the seminiferous tubules of the Cst−/− mice, whereas spermatogonia and primary spermatocytes seemed normal (Fig. (Fig.33C). The Leydig and Sertoli cells also seemed to be normal in Cst−/− mice. Late spermatocytes exhibited degeneration ranging from nuclear condensation to the formation of syncytial multinucleated cells at the metaphase of the first meiotic division (Fig. (Fig.33C, arrows), indicating an abrupt arrest of spermatogenesis during the late meiotic prophase in Cst−/− males. The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end-labeling assay indicated that the degenerating cells were undergoing apoptosis (Fig. (Fig.33D).

To verify the stages of the developmental arrest of spermatogenic cells in Cst−/− mice, the expression of spermatogenesis-marker genes was examined by semiquantitative RT-PCR analysis (Fig. (Fig.33E). Hlf3 (encoding histone H1t) is expressed in mid- to late-pachytene spermatocytes (22) and Sprm1 is transiently expressed from late-pachytene to diprotene (23). The transcripts from these genes were present in Cst−/− testes at the same levels as in the wild type. The Ccna1 (encoding cyclin A1) gene is expressed just before or during the first meiotic division (24). Cdc25c transcripts first appear in late pachytene-diprotene spermatocytes and are abundant in round spermatides (25). The messages for Ccna1 and Cdc25c were significantly reduced in the homozygous mutant mice as compared with wild-type and heterozygous mutant mice. Cst−/− testes completely lacked the haploid-specific Prm1 transcript (encoding protamine 1) (26), indicating that spermatogenesis of the mutant mice was blocked before the meiotic division. Thus, the results of the gene-expression experiments are consistent with the morphological observations in that the spermatogenesis of Cst−/− mice is arrested at the end of the meiotic prophase. The arrested stage in Cst−/− mice seems to be somewhat later than that in Cgt−/− mice, in which the metaphase of meiosis was not observed and the expression of late-pachytene spermatocyte-marker genes Hlf3 and Sprm-1 was reduced (16). These findings suggest that GalEAG and seminolipid are successively involved in the genetic program of spermatogenesis in the same order as their biosynthesis. Because these glycolipids are expressed on the cell surface of primary spermatocytes from the end of the leptotene stage or the zygotene stage and later (7, 8, 16), the interaction between Sertoli cells and spermatocytes, which is known to be important for their differentiation (27), may be disrupted in these knockout mice.

GalCer and sulfatide together constitute approximately 30% of total myelin lipid, and they are first expressed at a critical point during oligodendrocyte differentiation, when progenitors cease to proliferate and commence terminal differentiation. This fact leads to the prediction that these lipids play a role in the regulation of oligodendrocyte differentiation, in addition to their eventual roles as structural components of mature myelin. Indeed, oligodendrocyte differentiation is enhanced in CGT-knockout mice in vitro and in vivo, indicating that GalCer and/or sulfatide act as negative regulators of the entry of oligodendrocytes into terminal differentiation (28). Furthermore, the terminal differentiation was blocked by anti-sulfatide antibody O4 but not by anti-GalCer antibody O1 (28). These findings strongly suggest that sulfatide is a key regulator of the oligodendrocyte differentiation. This hypothesis must be certified by using CST-knockout mice.

The observed differences in phenotype between CGT- and CST-deficient mice revealed that GalCer and GalEAG act, not only as a precursor for sulfoglycolipid synthesis, but also as a functional molecule in myelin function and spermatogenesis, respectively. It also indicates that sulfate group-recognizing mechanisms are involved in such biological processes. By comparing the differences between CGT- and CST-deficient mice in detail, a differentiation in the molecular mechanisms in which the galactolipids and sulfoglycolipids are involved could be drawn. The quantitatively minor sulfated glycolipids include lactosylceramide sulfate and SM1b, which are found in the kidney and small intestine, respectively (7). Their sulfation is catalyzed by CST in vitro (10), whereas CGT is not involved in the biosynthetic pathway of these glycolipids. Therefore, a phenotype specific to CST-deficient mice had been expected. However, Cst−/− mice exhibited signs of neither renal failure nor digestive disorders, and they were able to survive for more than 1 year. No apparent histologic abnormality was noticed in the kidney and alimentary system. A detailed analysis is needed to elucidate the biological function of sulfated glycolipids in the kidney and alimentary canal. The significance of monogalactosyldiacylglycerol sulfate, which is present as a minor component in the brain of very young mice as well as in the testis (7), also remains to be investigated.

Because Cst-null mice are not embryonic lethal, a human disease with inherited CST deficiency may exist. Thus far, no such human neuropathological diseases have been mapped in the vicinity of the CST locus on chromosome 22q12 (13). The CST-knockout mouse may provide a symptomatic model for a search for a human CST deficiency.


We thank Ms. T. Usami and Ms. R. Okamoto for their help in injecting embryonic stem cells into blastocysts, Dr. Y. Nishimune for critical comments on the histologic observation of testis, and Dr. M. Taniike for help in tissue preparation for the morphological study of the nervous system. We are also grateful to Dr. K. Suzuki for his critical reading of this manuscript. This work was supported by grants from the Naito Foundation and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Priority Area 1078104) to K.H. and by Research Grants NS 27736 (to B.P.) and NS 24453 (to K.S.), and Mental Retardation Research Center Core Grant HD 03110 from the U.S. Public Health Service.


ceramide galactosyltransferase
cerebroside sulfotransferase
reverse transcription


1. Bullock S L, Fletcher J M, Beddington R S P, Wilson V A. Genes Dev. 1998;12:1894–1906. [PMC free article] [PubMed]
2. Humphries D E, Wong G W, Friend D S, Gurish M F, Qiu W T, Huang C, Sharpe A H, Stevens R L. Nature (London) 1999;400:769–772. [PubMed]
3. Forsberg E, Pejler G, Ringvall M, Lunderius C, Tomasini-Johansson B, Kusche-Gullberg M, Eriksson I, Ledin J, Hellman L, Kjellen L. Nature (London) 1999;400:773–775. [PubMed]
4. Tangemann K, Bistrup A, Hemmerich S, Rosen S D. J Exp Med. 1999;190:935–942. [PMC free article] [PubMed]
5. Akama T O, Nishida K, Nakayama J, Watanabe H, Ozaki K, Nakamura T, Dota A, Kawasaki S, Inoue Y, Maeda N, et al. Nat Genet. 2000;26:237–241. [PubMed]
6. Hemmerich S, Bistrup A, Singer M S, van Zante A, Lee J K, Tsay D, Peters M, Carminati J L, Brennan T J, Carver-Moore K, et al. Immunity. 2001;15:237–247. [PubMed]
7. Ishizuka I. Prog Lipid Res. 1997;36:245–319. [PubMed]
8. Vos J P, Lopes-Cardozo M, Gadella B M. Biochim Biophys Acta. 1994;1211:125–149. [PubMed]
9. Pfeiffer S E, Warrington A G, Bansal R. Trends Cell Biol. 1993;3:191–197. [PubMed]
10. Honke K, Yamane M, Ishii A, Kobayashi T, Makita A. J Biochem. 1996;119:421–427. [PubMed]
11. Honke K, Tsuda M, Hirahara Y, Ishii A, Makita A, Wada Y. J Biol Chem. 1997;272:4864–4868. [PubMed]
12. Hirahara Y, Tsuda M, Wada Y, Honke K. Eur J Biochem. 2000;267:1909–1916. [PubMed]
13. Tsuda M, Egashira M, Niikawa N, Wada Y, Honke K. Eur J Biochem. 2000;267:2672–2679. [PubMed]
14. Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Suzuki K, Popko B. Cell. 1996;86:209–219. [PubMed]
15. Bosio A, Binczek E, Stoffel W. Proc Natl Acad Sci USA. 1996;93:13280–13285. [PMC free article] [PubMed]
16. Fujimoto H, Tadano-Aritomi K, Tokumasu A, Ito K, Hikita T, Suzuki K, Ishizuka I. J Biol Chem. 2000;275:22623–22626. [PubMed]
17. Tohyama J, Vanier M T, Suzuki K, Ezoe T, Matsuda J, Suzuki K. Hum Mol Genet. 2000;9:1699–1707. [PubMed]
18. Committee on Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. Bethesda: Natl. Inst. Health; 1985. , DHHS Publ. No. (NIH) 85–23.
19. Kakuta Y, Pedersen L G, Carter C W, Negishi M, Pedersen L C. Nat Struct Biol. 1997;4:904–908. [PubMed]
20. Suzuki K, Zagoren J C. Brain Res. 1975;85:38–43. [PubMed]
21. Dupree J L, Coetzee T, Blight A, Suzuki K, Popko B. J Neurosci. 1998;18:1642–1649. [PubMed]
22. Kremer E J, Kistler W S. Exp Cell Res. 1991;197:330–332. [PubMed]
23. Andersen B, Pearse R V, II, Schlegel P N, Cichon Z, Schonemann M D, Bardin C W, Rosenfeld M G. Proc Natl Acad Sci USA. 1993;90:11084–11088. [PMC free article] [PubMed]
24. Ravnik S E, Wolgemuth D J. Dev Biol. 1999;207:408–418. [PubMed]
25. Wu S, Wolgemuth D J. Dev Biol. 1995;170:195–206. [PubMed]
26. Kleene K C, Distel R J, Hecht N B. Dev Biol. 1984;105:71–79. [PubMed]
27. Jegou B. Int Rev Cytol. 1993;147:25–96. [PubMed]
28. Bansal R, Winkler S, Bheddah S. J Neurosci. 1999;19:7913–7924. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • Gene
    Gene links
  • Gene (nucleotide)
    Gene (nucleotide)
    Records in Gene identified from shared sequence links
  • GEO Profiles
    GEO Profiles
    Related GEO records
  • HomoloGene
    HomoloGene links
  • MedGen
    Related information in MedGen
  • Nucleotide
    Published Nucleotide sequences
  • Pathways + GO
    Pathways + GO
    Pathways, annotations and biological systems (BioSystems) that cite the current article.
  • Protein
    Published protein sequences
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links
  • Taxonomy
    Related taxonomy entry
  • Taxonomy Tree
    Taxonomy Tree

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...